Is this the end of lifelong meds for Hep B?

For many people living with chronic hepatitis B, treatment has meant taking an antiviral medication every day for years—often indefinitely—to keep the virus suppressed. These medications remain highly effective and important, but they usually do not eliminate hepatitis B surface antigen (HBsAg), a key viral protein that signals ongoing infection.

That may be starting to change.

In October 2026, the FDA approved Hibsago (bepirovirsen), the first antisense oligonucleotide therapy for select adults with chronic hepatitis B. This new treatment is not a sterilizing cure—meaning it does not erase every trace of hepatitis B virus from the body—but it offers some patients the possibility of a hepatitis B functional cure after a defined treatment course.

A functional cure means that hepatitis B surface antigen is no longer detectable and HBV DNA remains suppressed after all hepatitis B medicines have been stopped. For patients who achieve this outcome, it may mean freedom from lifelong antiviral therapy, with continued long-term monitoring.

What Is Bepirovirsen (Hibsago)?

Bepirovirsen is a medication given by injection under the skin. It belongs to a class of medicines called antisense oligonucleotides.

Think of hepatitis B virus as using genetic “instructions” inside liver cells to make viral proteins and new viral particles. Bepirovirsen is designed to bind to those instructions—viral RNA—and interfere with the virus’s ability to produce key proteins, including HBsAg.

Reducing HBsAg matters because high levels of this protein can contribute to immune exhaustion. In simple terms, the immune system may have difficulty recognizing and controlling hepatitis B when it is continually exposed to large amounts of viral antigen. By substantially lowering HBsAg, bepirovirsen may give the immune system a better opportunity to regain control of the infection.

Why This Is Different From Traditional Chronic Hepatitis B Treatment

Current oral hepatitis B antiviral medicines are very effective at lowering HBV DNA, the amount of virus measurable in the blood. They reduce inflammation in the liver and lower the risk of cirrhosis, liver failure, and liver cancer.

However, for many patients, treatment must continue long term because the virus can reactivate after medication is stopped.

Hibsago is used with existing antiviral therapy, not as an immediate replacement for it. The goal is different: to achieve a durable response that may allow carefully selected patients to stop treatment while maintaining viral control.

This does not mean every patient with chronic hepatitis B will be able to stop medication. It does mean that, for the first time, a finite-treatment path toward functional cure is FDA-approved for a defined group of patients.

What Did the Clinical Trials Show?

The phase 3 B-Well studies evaluated bepirovirsen in adults with chronic hepatitis B who were already taking stable nucleos(t)ide analogue antiviral therapy.

Participants received bepirovirsen injections for 24 weeks while continuing their established hepatitis B medication. Eligible patients continued their oral antiviral for at least 24 weeks after their last bepirovirsen dose. Some patients who met specific clinical and laboratory criteria were then able to discontinue their oral antiviral therapy.

At 24 weeks after stopping all hepatitis B treatment, approximately 19% to 20% of patients receiving bepirovirsen achieved functional cure: HBV DNA remained below the limit of quantification and HBsAg was not detectable.

While this result is not a cure for everyone, it is a meaningful advance. Until now, sustained HBsAg loss after treatment has been uncommon with standard antiviral therapy alone.

Who May Be a Candidate for Hibsago?

Hibsago is approved for certain adults with chronic hepatitis B without cirrhosis. The FDA-approved patient-selection criteria include:

• Ongoing nucleos(t)ide analogue antiviral therapy for at least six months
• Suppressed HBV DNA while on antiviral therapy
• Quantitative HBsAg levels of 3,000 IU/mL or lower
• No cirrhosis

The HBsAg level is particularly important. It is more than a simple positive-or-negative hepatitis B test. A quantitative HBsAg test measures the amount of surface antigen in the blood and helps identify patients most likely to benefit from bepirovirsen.

In clinical studies, lower baseline HBsAg levels were associated with better chances of response. This is why baseline HBsAg testing is now central to deciding whether this treatment approach may be appropriate.

The FDA also authorized the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic to help identify eligible patients and monitor HBsAg levels during treatment.

How Is Hibsago Given?

Bepirovirsen is administered as a subcutaneous injection, meaning an injection into the fatty tissue just beneath the skin.

The approved dosing schedule is:

• Weeks 1–2: 300 mg injection twice weekly, spaced three or four days apart
• Weeks 3–24: 300 mg injection once weekly

Patients continue their existing hepatitis B antiviral medication during Hibsago treatment and for at least 24 weeks after the final Hibsago injection. Whether the oral antiviral can later be stopped depends on meeting strict treatment-response, liver-health, and laboratory criteria.

This process requires structured follow-up. Stopping hepatitis B therapy without appropriate monitoring can lead to viral relapse or liver inflammation.

What Are the Risks and Side Effects?

As with any potent chronic hepatitis B treatment, safety monitoring is essential.

Common side effects of Hibsago may include injection-site reactions, fever, fatigue, headache, flu-like symptoms, nausea, muscle aches, rash, and itching. Laboratory changes can include elevations in liver enzymes, reductions in platelet counts, and changes in kidney function.

Hibsago carries a boxed warning for serious liver reactions and low platelets, which can increase bleeding risk. It also has warnings related to kidney function, serious inflammatory reactions, and proper injection technique.

Regular blood testing before, during, and after treatment is necessary. This includes monitoring liver enzymes, bilirubin, platelet count, kidney function, HBV DNA, and HBsAg levels.

A Hopeful New Chapter—Not the End of Monitoring

Bepirovirsen represents a major step forward in chronic hepatitis B treatment. For eligible patients, it creates a realistic possibility of a treatment-free functional cure after a finite course of therapy.

Still, a functional cure is not the same as complete viral eradication. Hepatitis B follow-up remains important, particularly for patients with prior fibrosis, cirrhosis, a family history of liver cancer, or other liver-risk factors.

The key message is hopeful and practical: lifelong medication may no longer be the only path for every patient with chronic hepatitis B. Measuring HBsAg levels, assessing liver health, and selecting the right candidates can help determine whether Hibsago offers a path toward long-term viral control without ongoing antiviral treatment.

If you live with chronic hepatitis B and wonder whether this new treatment path could apply to you, call Gastro in Florida at (863) 824-3447 (Okeechobee) or (561) 767-8342 (Wellington), or book a televisit.

Sources

1. The New England Journal of Medicine, 2026
2. Journal of Hepatology, 2025
3. ClinicalTrials.gov — NCT04954859
4. ClinicalTrials.gov — NCT06497504
5. FDA — Hibsago (bepirovirsen) drug label, DailyMed
6. Annals of Internal Medicine, 2026
7. Nature Medicine, 2021
8. Hepatology, 2019
9. Clinical Infectious Diseases, 2024
10. Clinical Infectious Diseases, 2017
11. Hibsago US Prescribing Information (GSK/FDA)
12. Nature — news feature, 2026
13. FDA press announcement: FDA approves first-of-its-kind chronic hepatitis B treatment, 2026

---